Drug intelligence / Profile preview

Growth Hormone Therapeutic

Development stage: Preclinical
Lead developer: ASAKE Biotechnology
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Growth Hormone Therapeutic is a second-generation biologic candidate under development by ASAKE Biotechnology for the treatment of acromegaly. It functions as a dual receptor antagonist, targeting both the human growth hormone (hGH) receptor and the human prolactin (hPRL) receptor. By blocking these receptors, the therapeutic aims to normalize the pathological signaling associated with growth hormone overproduction. The program is currently in the preclinical stage of development and is designed to offer improved efficacy or safety over first-generation growth hormone receptor antagonists.

Other names: Growth Hormone Therapeutic (second-generation)

Targets

GHR (Growth hormone receptor)PRLR (Prolactin receptor)

Beyond the preview

Go deeper on Growth Hormone Therapeutic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Growth Hormone Therapeutic.

Explore the full profile